The blockade of immune checkpoints in cancer immunotherapy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews. Cancer

• Publication date

  2012-03-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc3239PMID 22437870PMCID PMC4856023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.

  2017cited by this paper
• The Role of Abiotic Environmental Conditions and Herbivory in Shaping Bacterial Community Composition in Floral Nectar

  2014cited by this paper
• Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

  2012cited by this paper
• CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

  2012cited by this paper
• Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

  2011cited by this paper
• Dual biological effects of the cytokines interleukin-10 and interferon-γ

  2011cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• LAG-3 in Cancer Immunotherapy.

  2011cited by this paper
• The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

  2011cited by this paper
• MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

  2011cited by this paper
• IL-18 induces PD-1-dependent immunosuppression in cancer.

  2011cited by this paper
• Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.

  2011cited by this paper
• Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

  2011cited by this paper
• The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival

  2011cited by this paper
• Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

  2011cited by this paper
• New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.

  2011cited by this paper
• Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

  2010cited by this paper
• Clinical development of the anti-CTLA-4 antibody tremelimumab.

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• Improved Endpoints for Cancer Immunotherapy Trials

  2010cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

  2010cited by this paper
• Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

  2010cited by this paper
• Fine tuning the immune response through B7‐H3 and B7‐H4

  2009cited by this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

  2009cited by this paper
• Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

  2009cited by this paper
• CD28 and CTLA‐4 coreceptor expression and signal transduction

  2009cited by this paper
• Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal

  2009cited by this paper
• Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1

  2009cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+

  2009cited by this paper
• Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

  2009cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

  2008cited by this paper
• A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

  2008cited by this paper
• IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

  2008cited by this paper
• Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade

  2008cited by this paper
• Up on the tightrope: natural killer cell activation and inhibition

  2008cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.

  2008cited by this paper
• Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

  2008cited by this paper
• Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature.

  2007cited by this paper
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

  2007cited by this paper
• LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma

  2007cited by this paper
• Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

  2007cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Foxp3-dependent programme of regulatory T-cell differentiation

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Missing self recognition and self tolerance of natural killer (NK) cells.

  2006cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.

  2006cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Reversal of the TCR Stop Signal by CTLA-4

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Corrigendum to “IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells” [J. Dermatol. Sci. 40 (2005) 95–103]

  2006cited by this paper
• Extending missing-self? Functional interactions between lectin-like NKrp1 receptors on NK cells with lectin-like ligands.

  2006cited by this paper
• Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells.

  2005cited by this paper
• In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

  2005cited by this paper
• Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors.

  2005cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

  2005cited by this paper
• The B7 family revisited.

  2005cited by this paper
• The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

  2005cited by this paper
• IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells.

  2005cited by this paper
• Role of LAG-3 in regulatory T cells.

  2004cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  2003cited by this paper
• Supporting Online Material

  2003cited by this paper
• BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

  2003cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

  2003cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Arginase Activity is Inhibited by l -NAME, both In Vitro and In Vivo

  2002cited by this paper
• Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

  2002cited by this paper

• Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer

  2026cites this paper
• The Application of PD‐1 Inhibitors in Immunotherapy for Glioblastoma

  2026cites this paper
• Hip osteoarthritis is not a risk factor for immune checkpoint inhibitor-induced inflammatory arthritis.

  2026cites this paper
• A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies

  2026cites this paper
• Diagnostic challenges in primary pulmonary follicular dendritic cell sarcoma: 2 case reports.

  2026cites this paper
• mRNA vaccines transform personalized lung cancer treatment.

  2026cites this paper
• Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review

  2026cites this paper
• Mechanotransduction of Piezo1 in the cancer microenvironment: implications for NK cell-based immunotherapy

  2026cites this paper
• Bibliometric analysis of ovarian cancer immune evasion research from 2015 to 2024

  2026cites this paper
• Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy

  2026cites this paper
• N-terphenylpicolinamide derivatives designed to target PD-L1 increase activation and proliferation of T cells, and their cytotoxic properties toward cancer cells.

  2026cites this paper
• Differentiation grade and combined positive score correlation in head and neck squamous cell carcinoma.

  2026cites this paper
• Functionalized Biomaterials in the Investigation of the Effects of Fluid Shear Forces in the Immune Regulation of Cancer Progression and Metastasis.

  2026cites this paper
• Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.

  2026cites this paper
• Immunotherapies for Central Nervous System Tumors and their Neurologic Complications

  2026cites this paper
• OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress

  2026cites this paper
• Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses.

  2026cites this paper
• Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

  2026cites this paper
• Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events

  2026cites this paper
• Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing

  2026cites this paper
• Advanced molecularly imprinted polymers for disease treatment via targeting molecular abnormalities: Promises and challenges

  2026cites this paper
• CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.

  2026cites this paper
• Metal–Organic Frameworks for Precision Phototherapy of Breast Cancer

  2026cites this paper
• Global trends of peripheral immune tolerance research: a bibliometric and visualization analysis.

  2026cites this paper
• ICIsc: A Deep Learning Framework for Predicting Immune Checkpoint Inhibitor Response by Integrating scRNA-Seq and Protein Language Models.

  2026cites this paper
• Semaphorins: from CD8⁺ T cells to cancer immunotherapy

  2026cites this paper
• Precision management of cervical cancer emphasizes immunotherapy combination regimens and translational advances.

  2026cites this paper
• Nuclear PD-L1 regulates YAP-driven transcription via the PGE2-EP4-YAP-importin α3 axis in solid tumors.

  2026cites this paper
• The signal hijacker: How tumors co-opt chemical, electrical, and mechanical cues to thrive.

  2026cites this paper
• Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

  2026cites this paper
• Advances in nano‑molybdenum oxide: structural engineering progress in tumor theranostics

  2026cites this paper
• Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

  2026cites this paper
• Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance

  2026cites this paper
• Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.

  2026cites this paper
• Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

  2026cites this paper
• Mesoporous Silica: A Promising Adjuvant for Cancer Vaccines.

  2026cites this paper
• Paraneoplastic neurologic disorders and neurologic complications of immune checkpoint inhibitors.

  2026cites this paper
• Solvent osmolarity and viscosity regulate lymph node pharmacokinetics and perinodal dynamics in lymphatic drug delivery.

  2026cites this paper
• Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology

  2026cites this paper
• Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer

  2026cites this paper
• Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics

  2026cites this paper
• Past, present, and future of immunotherapy research in liver neoplasms: A bibliometric and visualization analysis

  2026cites this paper
• Checkpoint inhibitors in cancer Immunotherapy: Mechanisms, Resistance, and Combination Strategies

  2026cites this paper
• Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma

  2026cites this paper
• Positron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design

  2026cites this paper
• Expression and Functional Analysis of Anti-Human PD-1 Monoclonal Antibody in Transgenic Plants.

  2026cites this paper
• Caged Ligand-Decorated Near-Infrared Photosensitizer with In Vivo Albumin-Hijacking Capacity for Tumor-Targeted Hypoxia-Tolerant Photoimmunotherapy of Cancer.

  2026cites this paper
• Mechanisms and strategies for reversing NK cell exhaustion in tumor immunotherapy.

  2026cites this paper
• Reprogrammed Fibrotic Niche Fuels Lung Cancer Initiation and Reciprocal Remodeling

  2026cites this paper
• Loss of XRCC1 promotes cGAS/STING mediated innate immune signaling in gastric cancer.

  2026cites this paper
• Biomarkers of Immunotherapy Response in Surgical Oncology

  2026cites this paper
• Molecular Landscape of Resected Thymomas: Insights from Mutational Profiling

  2026influential citation
• Advancing the understanding of the immune escape in lung cancer immunotherapy: Global trends, collaborations, and future directions

  2026cites this paper
• Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer

  2026cites this paper
• Exploring FDA-approved small molecules for their potential as PD-1/PD-L1 inhibitors: integrating computational screening with experimental testing

  2026cites this paper
• T‐Cell Immunity and Lung Cancer

  2026cites this paper
• Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer : Author list.

  2026cites this paper
• Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer.

  2026cites this paper
• ProMMF_Kron: a multimodal deep learning model for immunotherapy response prediction in stomach adenocarcinoma.

  2026cites this paper
• Immune Checkpoint Inhibitors Did Not Exacerbate Autoimmune Rheumatic Disease Activity in Patients With Cancer.

  2026cites this paper
• Influence of the tumor microenvironment on genetic mutations in thyroid carcinoma

  2026cites this paper
• Tuning tissue-resident memory T cells to fuel cancer immunotherapy.

  2026cites this paper
• Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy

  2026cites this paper
• Neoadjuvant Chemoimmunotherapy.

  2026cites this paper
• PTPN22 Dephosphorylates CBL to Inhibit PD-L1 Ubiquitination and Drive Immunosuppression in Renal Cell Carcinoma

  2026cites this paper
• Evaluating Nuclear Levels of PD-L1 in Ovarian Cancer Cells by Western Blotting.

  2026cites this paper
• Microbiome modulation of tumorigenesis and immune responses

  2026cites this paper
• Reconstituting the head and neck tumor microenvironment with air-liquid interface organoids

  2026cites this paper
• Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances.

  2026cites this paper
• Long-term complete response of early gastric cancer to nivolumab: report of a case with disease-free survival for six years.

  2026cites this paper
• Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review)

  2026cites this paper
• Akkermansia muciniphila enhances the antitumour efficacy of αPD-1 therapy in gastric cancer by remodelling the tumour immune microenvironment.

  2026cites this paper
• Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer

  2026cites this paper
• FoxO3a‐Mediated Modulation of PD‐L1 Expression and Inhibition by Dihydroartemisinin in Triple‐Negative Breast Cancer

  2026cites this paper
• T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.

  2026cites this paper
• Biliary disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

  2026cites this paper
• Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.

  2026cites this paper
• Microbiota-induced T cell plasticity enables immune-mediated tumour control

  2026cites this paper
• Detection of PD-1 and CD28 Expression in Lymphocytes by Flow Cytometry.

  2026cites this paper
• Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody–drug conjugates, and clinical trial innovations

  2026cites this paper
• PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.

  2026cites this paper
• High-payload trastuzumab-drug conjugates achieved through hydrophilic Y-shaped pendant PEG linkers for a potent and selective antitumor response.

  2026cites this paper
• A study on the role of cuproptosis-related immune checkpoint genes in non-small cell lung cancer

  2026cites this paper
• Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

  2026cites this paper
• Discovery of Seven ROS-Sensitive Immune Checkpoints and 46 Ligands Mediating Immune Suppression Through T cell-APC Networks

  2026cites this paper
• Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

  2026cites this paper
• Tumor microenvironment heterogeneity and immunotherapy resistance: multidimensional modulation strategies for precision breakthroughs

  2026cites this paper
• T-cell exhaustion due to BiTE therapy in multiple myeloma: mitigating infectious risks through treatment-free intervals

  2026cites this paper
• Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.

  2026cites this paper
• A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region

  2026influential citation
• A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer

  2026cites this paper
• The role of CD26 in breast cancer and its pan-cancer analysis

  2026cites this paper
• Differences in immune indicators among normal, high-risk, and esophageal cancer populations and development of a predictive model

  2026cites this paper
• LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

  2026cites this paper
• PD-L1 expression and tumor-infiltrating T lymphocytes as prognostic factors in canine mammary tumors.

  2026cites this paper
• Elevated TIGIT Expression and Immune Cell Dysfunction Characterize COMPASS-like Complex Gene-mutated Pancreatic Ductal Adenocarcinoma.

  2026cites this paper
• Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.

  2026cites this paper
• Dual Immunological Prognostic Models for Risk Stratification and Treatment Insights in Triple-Negative Breast Cancer

  2026cites this paper
• UNC93B1 promotes pancreatic cancer progression through modulation of cGAS-STING signaling.

  2026cites this paper
• The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma

  2026cites this paper